Geron (GERN) Work In Process (2024)
Geron's (GERN) quarterly Work In Process came in at $30.1 million in Q4 2024, up 122.19% quarter-over-quarter from $13.5 million in Q3 2024.
Powered by 
Analysis
Geron (GERN) Work In Process (2024) Analysis & Trends
Geron has disclosed Work In Process across 1 years of filings, most recently posting $30.1 million for Q4 2024.
- In Q4 2024, Work In Process changed N/A year-over-year to $30.1 million; the TTM figure through Dec 2024 stood at $30.1 million (changed N/A YoY), while the FY2024 annual figure was $30.1 million, changed N/A from the prior year.
- Work In Process came in at $30.1 million for Q4 2024 at Geron, up from $13.5 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $30.1 million in Q4 2024 to a low of $13.5 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - |